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Abstract A hypofunctionality of Gi proteins has been
found in migraine patients. The fixed combination of
indomethacin, prochlorperazine and caffeine (Indoprocaf)
is a drug of well-established use in the acute treatment of
migraine and tension-type headache. The aim of this study
was to investigate if Indoprocaf was able to exert its central
antinociceptive action when Gi proteins activity is abol-
ished by pertussis toxin (PTX), compared to its single
active ingredients and to sumatriptan. The mice model of
abdominal constriction test induced by an i.p. injection of a
0.6% solution of acetic acid was used. The study showed
that Indoprocaf (a fixed combination of indomethacin
1 mg/kg, prochlorperazine 1 mg/kg and caffeine 3 mg/kg,
s.c.) and sumatriptan (20 mg/kg, s.c.) exert their central
antinociceptive action independently from the Gi proteins.
In addition, the antinociceptive efficacy of Indoprocaf in
this study was statistically superior to that of sumatriptan.
This study also showed that the single active ingredients of
Indoprocaf, indomethacin (1 mg/kg, s.c.), prochlorperazine
(1 mg/kg, s.c.) and caffeine (3 mg/kg, s.c.), were able to
exert their central antinociceptive action independently
from the Gi proteins. However, Indoprocaf at analgesic
doses was able to abolish almost completely the abdominal
constrictions, with a statistically higher efficacy compared
to the single active ingredients, showing an important
synergic effect of Indoprocaf. This synergic effect was
evident not only when Gi proteins activity was abolished
by PTX, but also under control condition, when Gi proteins
were active. This study suggests that the central antinoci-
ceptive action induced by antimigraine drugs is indepen-
dent from Gi proteins.
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Introduction
It is worldwide recognized that specific drugs are the most
effective in the acute treatment of migraine, in particular in
patients with moderate or severe pain [1]. The fixed com-
bination of indomethacin, prochlorperazine and caffeine
(hereinafter Indoprocaf) is a drug of well-established use in
Italy, with a recognized efficacy and a good level of safety
both in the acute treatment of migraine [2, 3] and tension-
type headache [4].
In contrast to other non-steroidal anti-inflammatory
drugs (NSAIDs), indomethacin has an indole nucleus
which is similar to serotonin and to the 5HT1B/1D agonists
known as triptans. The efficacy of indomethacin in the
treatment of migraine and other primary headaches might
be due to its central analgesic activity [5], its ability to
abolish peripheral and central hyperalgesia [6–8], its
vasoconstrictive effect on cerebral vessels [9–11] and its
ability to inhibit neurogenic inflammation [12]. The
mechanism of action of prochlorperazine in migraine could
be attributed to its central cholinergic analgesic effect [13]
and to its ability to abolish hyperalgesia [6, 7]. Caffeine is
used as an effective analgesic adjuvant in various analgesic
combinations. It is a non-selective antagonist of adenosine
A1 and A2 receptors [14]. Its positive effects in the
symptomatic treatment of headache are attributed to an
C. Ghelardini  N. Galeotti  E. Vivoli
Department of Pharmacology, University of Florence,
Viale G. Pieraccini, 6, 50139 Florence, Italy
I. Grazioli  C. Uslenghi (&)
Medical Department, Solvay Pharma S.p.A.,
Via della Liberta`, 30, 10095 Grugliasco, Torino, Italy
e-mail: carla.uslenghi@solvay.com
123
J Headache Pain (2009) 10:435–440
DOI 10.1007/s10194-009-0151-1
increased analgesic action of other drugs [14], a central
cholinergic analgesic effect [15], its ability to abolish
hyperalgesia [6] and a vasoconstrictive activity [16].
Indoprocaf, administered i.p. at sub-analgesic doses in
mice, showed to be able to reverse hyperalgesia induced by
morphine withdrawal and to be superior to each single
active ingredient in abolishing hyperalgesia induced by a
0.3% solution of acetic acid i.p. injected [6]. Moreover,
Indoprocaf, but not sumatriptan, administered i.p. at sub-
analgesic doses in mice, was able to abolish peripheral and
central sensitization [7].
Nearly all inhibitory neurotransmitters which are able to
enhance the pain threshold use Gi proteins as signal
transduction system. Gi proteins reduce neurones excit-
ability through the inhibition of adenylate cyclase activity
and modulation of several K? and Ca2? channels [17]. A
hypofunctionality of Gi proteins has been found in lym-
phocytes of patients with migraine and cluster headache
[17]. The intracerebroventricular administration of pertus-
sis toxin (PTX) selectively inhibits Gi proteins and blocks
the antinociceptive action of common analgesic drugs such
as opioids (morphine), histamine H1 receptor antagonists
(diphenhydramine), GABAB agonists (baclofen), tricyclic
antidepressants (clomipramine), but not of cholinesterase
inhibitors (physostigmine), in the mouse hot plate test
[18, 19].
The aim of this study was to investigate if Indoprocaf
was able to exert its central antinociceptive action when Gi
proteins activity is inactivated by PTX, compared to its
single active ingredients and to sumatriptan, in the mice
model of abdominal constriction test induced by a 0.6%
solution of acetic acid i.p. injected.
Methods
Animals
Male albino mice (20–25 g) from Morini breeding farm
(San Polo d’Enza—Italy) were used. All experiments were
carried out according to the guidelines of the European
Community Council Directive dated November 24, 1986
(86/609/EEC) for experimental animal care. All efforts
were made to minimize suffering and to reduce the number
of animals used.
Pertussis toxin administration
Mice were randomly assigned to the intracerebroventricu-
lar administration of PTX (0.25 lg per mouse) or to a
saline solution 9 days before the abdominal constriction
test. Intracerebroventricular administration was performed
under ether anaesthesia using isotonic saline as a solvent,
according to the method of Haley and McCormick [20].
During anaesthesia, mice were grasped firmly by the loose
skin behind the head. A 0.4-mm external diameter hypo-
dermic needle attached to a 10-ll syringe was inserted
perpendicularly through the skull and no more than 2 mm
into the brain of the mouse, where 5 ll were then admin-
istered. The injection site was 1 mm to the right or left
from the midpoint on a line drawn through to the anterior
base of the ears. Injections were performed into the right or
left ventricle randomly. To ascertain that the drugs were
administered exactly into the cerebral ventricle, some mice
were injected with 5 ll of Indian ink diluted 1:10 and their
brains were examined macroscopically after sectioning.
Drugs
The following drugs were used: indomethacin (non-ste-
roidal anti-inflammatory drug—Sigma, Milan, Italy), pro-
chlorperazine (D2-antagonist—Sigma, Milan, Italy),
caffeine (adenosine antagonist—Sigma, Milan, Italy),
sumatriptan (5-HT1B/1D agonist—GlaxoSmithKline) and
PTX (RBI).
The doses of the tested drugs were chosen on the basis
of their analgesic efficacy in the 0.6% solution of acetic
acid-induced abdominal constriction test: indomethacin
(1 mg/kg, s.c.), prochlorperazine (1 mg/kg, s.c.) [13], caf-
feine (3 mg/kg, s.c.) [15] and sumatriptan (20 mg/kg, s.c.)
[21] (Table 1). A fixed combination of indomethacin
(1 mg/kg), prochlorperazine (1 mg/kg) and caffeine
(3 mg/kg) was s.c. administered.
According to their pharmacokinetics, in order to reach
the analgesic peak in correspondence of the abdominal
constriction test, the tested drugs were s.c. administered
Table 1 Analgesic and antihyperalgesic doses of indomethacin, prochlorperazine and caffeine as Indoprocaf, and sumatriptan
Analgesic doses from
the literature (mg/kg)
Analgesic doses in the PTX
experiment (mg/kg)
Antihyperalgesic
doses (mg/kg)
Oral antimigraine doses
in the clinical practice (mg)
Indomethacin 1 [23] 1 0.1 [7] 25 [3]
Prochlorperazine 1–2 [13] 1 0.1 [7] 2 [3]
Caffeine 1–5 [15] 3 0.3 [7] 75 [3]
Sumatriptan 10–30 [21] 20 1 [24] 50 [3]
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30 min (prochlorperazine and sumatriptan) or 15 min
(indomethacin, caffeine and Indoprocaf) before the acetic
acid injection. A control group was treated with a saline
solution.
Abdominal constriction test
Mice were intraperitoneally injected with a 0.6% solution
of acetic acid (10 ml/kg) according to the method of Koster
[22]. The analgesic effect was evaluated through the count
of abdominal constrictions. The number of stretching
movements was counted for 10 min, starting 5 min after
the acetic acid injection. Ten animals per group were used.
Statistics
Results from abdominal constriction tests are given as the
mean ± SEM. Analysis of variance (ANOVA), followed
by Fisher’s PLSD procedure for post-hoc comparison, was
used to verify the significance between two means.
P-values of less than 0.05 were considered significant. Data
were analyzed with the StatView program (version 4.01)
for the Macintosh computer.
Results
In the abdominal constriction test, indomethacin (1 mg/kg,
s.c.), prochlorperazine (1 mg/kg, s.c.) and caffeine (3 mg/
kg, s.c.) induced a statistically significant central antino-
ciceptive effect also when the Gi proteins were inactivated
(Table 2), due to the administration of PTX, in comparison
with the control group.
Also sumatriptan (20 mg/kg, s.c.) was able to reduce
significantly the abdominal constrictions when the Gi
proteins were inactivated by the PTX (Table 2; Fig. 1).
The combination of indomethacin (1 mg/kg), prochlor-
perazine (1 mg/kg) and caffeine (3 mg/kg), s.c. adminis-
tered, induced a statistically significant reduction of
abdominal constrictions even when the Gi proteins were
inactivated by the PTX (Table 2; Fig. 2). The reduction
induced by the combination was statistically superior to
that of each of its single active ingredients and to that of
sumatriptan (Table 2; Fig. 3). Moreover, also when used as
analgesic in the control group (saline ? drug), the com-
bination of indomethacin, prochlorperazine and caffeine
induced a superior antinociceptive effect than that obtained
with the same analgesic dose of each single active ingre-
dient and than sumatriptan (Table 2).
Discussion
The aim of this study was to investigate if Indoprocaf was
able to exert its central antinociceptive action when Gi
proteins activity is abolished by PTX, compared to its
single active ingredients and to sumatriptan, in the mice
model of abdominal constriction test induced by an i.p.
injection of 0.6% solution of acetic acid. This study
showed that Indoprocaf and sumatriptan at analgesic doses
exert their central antinociceptive action independently
from the Gi proteins. In addition, the antinociceptive effi-
cacy of Indoprocaf in this study was statistically superior to
that of sumatriptan.
This study also showed that the single active ingredients
of Indoprocaf, indomethacin, prochlorperazine and caf-
feine, were able to exert their central antinociceptive action
independently from the Gi proteins.
Considering that prochlorperazine and caffeine induce a
central cholinergic analgesia [13, 15] and that the central
cholinergic system was proven to have a role in the an-
tinociception induced by sumatriptan in rodents [21], these
Table 2 Effect of indomethacin, prochlorperazine, caffeine, Indoprocaf and sumatriptan in mouse abdominal constriction test, with and without
pertussis toxin (PTX) (mean ± SEM)
No. of abdominal constrictions
Saline/saline PTX/saline Saline/drug PTX/drug
Indomethacin (1 mg/kg, s.c.) 31.4 ± 4.2 33.5 ± 2.3 16.1 ± 3.3* 13.8 ± 3.7
Prochlorperazine (1 mg/kg, s.c.) 27.1 ± 3.3 31.6 ± 2.4 15.1 ± 2.6* 16.6 ± 3.0
Caffeine (3 mg/kg, s.c.) 30.1 ± 1.3 31.5 ± 4.1 14.8 ± 3.3* 17.5 ± 2.9
Sumatriptan (20 mg/kg, s.c.) 28.6 ± 3.7 29.8 ± 3.1 13.2 ± 2.9* 14.4 ± 2.7
Indoprocaf (1/1/3 mg/kg, s.c.) 28.3 ± 1.6 27.8 ± 2.0 3.9 ± 1.1*§ 5.5 ± 1.7^
* P \ 0.01 vs. the corresponding saline/saline
 P \ 0.01 vs. the corresponding PTX/saline
§ P \ 0.01 vs. Saline/Indomethacin or saline/prochlorperazine or saline/caffeine or saline/sumatriptan
^ P \ 0.01 vs. PTX/indomethacin or PTX/prochlorperazine or PTX/caffeine or PTX/sumatriptan
ANOVA
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results are consistent with previous data showing that PTX
had no effect on cholinergic drugs-induced analgesia [19].
To our knowledge, no other NSAID besides indomethacin
has been tested in in vivo models of PTX-induced Gi
proteins inactivation.
Moreover, this study showed that Indoprocaf at anal-
gesic doses was able to abolish almost completely the
abdominal constrictions, with a statistically superior effi-
cacy compared to the single active ingredients, showing an
important synergic effect of Indoprocaf. This synergic
effect was evident not only when Gi proteins activity was
abolished by PTX, but also under control condition, when
Gi proteins were active. A synergic action of Indoprocaf at
sub-analgesic doses, compared to its single active ingre-
dients, was also proven in mice in the hyperalgesia model
induced by the intraperitoneal injection of a 0.3% solution
of acetic acid [6].
The dosages used for Indoprocaf in this experimental
model are in the range of effective analgesic doses
[13, 15, 23] and are 10 times higher than those shown to
be able to revert hyperalgesia [6, 7]. The dose of suma-
triptan used in this experimental model is in the range of
effective analgesic doses [21] and is 20 times higher than
that shown to revert hyperalgesia [24] (Table 1). From a
clinical point of view, the therapeutic doses (orally
administered) of indomethacin (25 mg), prochlorperazine
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(2 mg) and caffeine (75 mg) contained in Indoprocaf as
antimigraine drug are much lower than the range of doses
of indomethacin (50–200 mg daily) when used to treat
rheumatoid arthritis or pain of various aetiologies, of
prochlorperazine (15–50 mg daily) when used as antie-
metic and of anhydrous caffeine (100–200 mg) when used
in analgesic preparations (Table 1). These dosages are
consistent with the concept that migraine is a particular
pain characterized by neuronal hyperexcitability and that
migraine should be treated with specific drugs at dosages
that could be sub-analgesic, but are antihyperalgesic [7].
Moreover, this study shows first that Indoprocaf is supe-
rior to its single active ingredients also at analgesic doses,
supporting that, when used in the clinical practice, the
doses of active ingredients in Indoprocaf could be lower
than those of the single active ingredients when admin-
istered independently.
The central antinociceptive action exerted by Indoprocaf
and sumatriptan independently from Gi proteins might be
clinically important considering that it has been shown that
in migraine patients there is a hypofunctionality of Gi
proteins [17].
A hypofunctionality of Gi protein system has been
reported also in patients suffering from fibromyalgia
[25], and a high incidence of fibromyalgia was found
among female migraine patients [26]. Many chronic pain
syndromes, as fibromyalgia and chronic tension-type
headache, show evidence of central nervous system
hyperexcitability related to central sensitization [27, 28].
The efficacy of Indoprocaf both independently from the
Gi protein functionality and in abolishing the central sen-
sitization induced by N-methyl-D-aspartate (NMDA) in the
experimental animal model [7] could imply a potential
therapeutic value not only in migraine and tension-type
headache but also in fibromyalgia, three conditions sharing
some common features as an hyperalgesic state showing as
increased pain sensitivity [29, 30].
Conclusion
This study suggests that the central antinociceptive action
exerted by Indoprocaf and sumatriptan is independent from
Gi proteins. The superiority of Indoprocaf compared to
sumatriptan in this in vivo model supports the recent
clinical evidence that Indoprocaf most likely has similar
therapeutic efficacy to sumatriptan [31, 32], recognizing
therefore the role of Indoprocaf in the acute treatment of
migraine.
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